The present invention is directed to selective dopamine reuptake inhibitors, including (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexan- e, (-)-1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane, and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine, and methods of their use for treating certain nervous system disorders and conditions, including, inter alia, vasomotor symptoms (VMS), chronic pain, and Shy Drager syndrome.